We are live on ! Find out more
CMMB

Chemomab Therapeutics
CMMB

15 hedge funds and large institutions have $7.14M invested in Chemomab Therapeutics in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

193% more capital invested

Capital invested by funds: $2.44M → $7.14M (+$4.7M)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

7% more funds holding

Funds holding: 14 → 15 (+1)

0.16% more ownership

Funds ownership: 0.23% → 0.4% (+0.16%)

Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
3
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
+$1.7M
2
YLHM
Yelin Lapidot Holdings Management
Israel
+$1.14M
3
Morgan Stanley
Morgan Stanley
New York
+$554K
4
TSS
Two Sigma Securities
New York
+$56K
5
HF
HRT Financial
New York
+$19K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$701K
2
Citadel Advisors
Citadel Advisors
Florida
-$57.4K
3
Two Sigma Investments
Two Sigma Investments
New York
-$22.3K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$16.5K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$10.8K

CMMB Hedge Fund Activity: Q3 2024 in Review

15 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Chemomab Therapeutics (CMMB) for Q3 2024, worth a combined $7.14M — up 193% from $2.44M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CMMB positions and 6 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Sphera Funds Management, opening a new position worth an estimated $1.7M. The largest seller was OrbiMed, cutting an estimated $701K.

  • 15 institutional investors held Chemomab Therapeutics (CMMB) as of Q3 2024, up from 14 in Q2 2024.
  • Funds reported $7.14M of Chemomab Therapeutics stock for Q3 2024, up 193% quarter-over-quarter.
  • 7 funds opened new Chemomab Therapeutics positions in Q3 2024 and 6 closed out, a net change of +1 holder.
  • The largest Chemomab Therapeutics buyer in Q3 2024 was Sphera Funds Management, an estimated $1.7M added.
  • The largest Chemomab Therapeutics seller in Q3 2024 was OrbiMed, an estimated $701K sold.

Based on aggregated 13F filings for Q3 2024.